ASCO 2020：11项华南地区研究入选口头报告，17项Poster报告

不受全球新冠霍乱因素，延后于5月29日~6月2日在芝加哥举行的宾夕法尼亚州医学学会（ASCO）高峰会今年将首次以该线上形式举办，这是现有最大规模的该线上盛会。今天，全会的概述题目公布，合共103个sessions，中的国合分别为11项研究者入围口头报告，17项入围Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或佩佩替尼加卡培他滨用做HER2+结核乳腺乳癌（PHOEBE）：一项III期随机试验性。

第二场：结核乳腺乳癌

译者：中的国医学科学院诊所徐兵河研究者员、马飞研究者员，华东师范大学附设诊所胡夕春研究者员等

概述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可疗程三比如说乳腺乳癌标准外科疗程后卡培他滨保持稳定节拍低剂量的III期试验性（SYSUCC-001）。

第二场：乳腺乳癌—全局/地区/主要用途外科疗程

译者：中的文系防治地区内王树森研究者员等

概述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

为了让结核脑部的表型特征来计算脑部脊液中的反转DNA检测的几率: 新方法对抗老对手

第二场：新方法解决老问题

译者：刘美芹 刘德兰等

概述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

伊克非尼对里拉拉非尼作为后期肝巨噬细胞乳癌的中卫外科疗程：一项闭馆页面、随机、多地区内II/III期试验性。

第二场：呼吸道乳癌—十二指肠食道、凋亡和自是

译者：南京大学棱果诊所毕锋研究者员、团结解放军南开诊所秦叔逵研究者员等

概述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中的国后期肝乳癌病患者阿帕替尼主干该线外科疗程：一项随机、双盲相符合、双盲III期研究者

第二场：呼吸道乳癌—十二指肠食道、凋亡和自是

译者：团结解放军南开诊所秦叔逵研究者员、南京大学棱果诊所刘秋研究者员等

概述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后期开刀性卵巢乳癌二次巨噬细胞减灭术的一项随机III期试验性：SOC1 / SGOG-OV2。

为题：妇产科乳十二指肠癌

译者：华东师范大学附设中的山诊所臧荣余研究者员等

概述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治性子宫切除术后主要用途外科疗程中的的序贯放低剂量对比原则上放疗或不间断放低剂量（STARS研究者）：一项随机、相符合、闭馆页面的III期试验性。

全会：妇产科乳十二指肠癌

译者：中的文系防治地区内黄鹤研究者员、刘继红研究者员等

概述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：主要用途吉非替尼对比低剂量用做可切除的EGFR基因型的N1-N2期NSCLC-随机III期医学试验性的之后总体求生量化。

为题：肺乳癌—非小巨噬细胞全局-地区/小巨噬细胞/其他胸部

译者：广东省团结诊所吴一龙研究者员等

概述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因型俱转移非小巨噬细胞肺乳癌病患者中卫过氧化物激酶衍生物合组或不合组积极前该线全局放疗：III期闭馆页面医学随机试验性（SINDAS）的中的期结果（NCT02893332）。

为题：肺乳癌-非小巨噬细胞转移

译者：四川省团结诊所曾铭研究者员等

概述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性死亡-1（PD-1）的人源化IgG4抗病毒合组阿昔替尼用做结核皮肤卵巢乳癌病患者的Ib期研究者的总求生期和生物研究者课题量化。

为题：卵巢乳癌/皮肤乳癌

译者：中国人民大学诊所郭军、盛锡楠研究者员等

概述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的可用性和结果：通用CAR-T巨噬细胞首次生物体试验性外科疗程开刀/难治性T巨噬细胞急性淋巴巨噬细胞白血病（r/r T-ALL）的可用性和。全会：研发中的的外科疗程技术-免疫外科疗程。译者：王恰巧等概述：3013的广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利他汀在后期食道突起巨噬细胞乳癌病患者中的的广泛应用：一项随机的闭馆页面II期试验性（ORIENT-2）。全会：呼吸道乳癌-十二指肠食道乳癌、凋亡乳癌和自是道乳癌译者：徐建明研究者员等概述：4511的广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T巨噬细胞对髓母巨噬细胞病变的根除性外科疗程全会：中的枢神经系统译者：代红久、孙斌、杨东、徐晖、朱小妹、魏佳、杨旭东概述：2522的广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后期错配修复不足之处病患者中的的广泛应用全会：研发中的的外科疗程学-免疫外科疗程译者：沈琳研究者员等概述：3021的广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 增生CD7-CART外科疗程开刀/难治性ACUTE淋巴巨噬细胞白血病/霍奇金的首例生物体医学试验性全会: 研发性外科疗程学-免疫外科疗程译者简介：张明志，南部县等概述：3026的广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度酰（T）合组广泛应用做后期实体病变病患者的Ib期研究者全会：发展性外科疗程学；还有分子靶向药物和生物学译者：龚继芳，沈琳研究者员等概述：3523的广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin合组紫杉醇和nedaplatin外科疗程开刀性或结核食道突起巨噬细胞乳癌（ESCC）病患者的II期研究者。全会：呼吸道乳癌-十二指肠食道、凋亡和自是道乳癌的研究者译者：王志过关斩将，刘玉红，王德申，王凤华，任超，谭琼 王志过关斩将、刘玉红、王德深、王凤华、任超、谭琼概述：4522的广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全会：呼吸道乳癌-十二指肠食道乳癌、凋亡乳癌和自是管乳癌的主干该线外科疗程译者：宋艳等概述：4524的广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体环状RNA分类器用做初始活检时检测高等级乳癌的尿液外体环状RNA分类器：一项多地区内的回顾性研究者全会：心脏胎盘乳十二指肠癌；还有-乳癌、睾丸乳癌和乳癌译者简介：Liaoyuan Li等概述：5522的广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 全局后期宫颈乳癌并发低剂量后的主要用途低剂量全会: 妇产科乳十二指肠癌译者简介： 刘珉珉等概述：6031的广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼外科疗程甲状腺髓性乳癌的持续性：基于ALTER01031试验性的量化。会话：胸部译者：天津市诊所霸道研究者员概述：6526的广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和成年对安洛替尼外科疗程后病患者结局的因素: ALTER01031的亚组量化全会：胸部译者：天津市诊所霸道研究者员概述：6527的广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA量化计算I-IIIA期非小巨噬细胞肺乳癌（NSCLC）病患者术后开刀: GASTO1035和GASTO1018的结果全会：肺乳癌-非小巨噬细胞全局-地区性/小巨噬细胞/小巨噬细胞/其他胸科乳十二指肠癌译者：Si-Yu Wang等概述：9023的广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小巨噬细胞肺乳癌（NSCLC）中的EGFR过氧化物激酶衍生物的新型耐药机制全会:肺乳癌-非小巨噬细胞结核肺乳癌译者简介：杨昕，金结缘，满宇，欧元人，华宝，薛武，杨少，范敏 杨昕、金结缘、满宇、欧元人、华宝、薛武、杨绍、范敏概述：9528的广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验性中的后期卵巢乳癌总求生的替代往南全会：卵巢乳癌/皮肤乳癌译者：聂润聪，袁书过关斩将，刘元芳，陈英波，周志伟 聂润聪、袁书过关斩将、刘元芳、陈英波、周志伟概述：10030的广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼外科疗程开刀或结核临床表现恶性骨病患者的II期研究者全会： 肉病变译者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、曹吉祥、蔡启庆、涂崇奇、范正福、杨瑶概述：11525的广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 现阶段评价安罗替尼在后期肉病变病患者多该线外科疗程中的的可用性和。全会：肉病变译者：姚伟涛，陈家过关斩将，张鹏，斌，杜新辉，田志浩，牛晓颖 姚伟涛、陈家过关斩将、张鹏、王鑫、杜鑫辉、田志超、牛晓英概述：11526的广告：414